BioRestorative Therapies to Present Preclinical Data from its ThermoStem® Brown Fat Stem Cell Program at Annual Meeting of the International Federation for Adipose Therapeutics and Science

Download as PDF

JUPITER, Fla.--(BUSINESS WIRE)-- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB:BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, announces that preclinical data on its ThermoStem® brown fat stem cell program will be presented November 22nd at the 11th Annual Meeting of the International Federation for Adipose Therapeutics and Science (iFATS) in New York City. The meeting will take place November 21-24 at the Conrad Hotel New York and will bring together leading scientists and decision-makers in the exciting field of adipose stem cell research to learn about the latest scientific, medical and technological advances.

BRT Chief Scientist and Vice President of Research and Development, Francisco Silva, will be presenting preclinical data from the Company’s ThermoStem® program that focuses on treatments using brown fat stem cells for metabolic disorders and obesity, primarily for the prevention of type 2 diabetes.

“We are very excited to be presenting new data at such an important meeting. Acceptance of our research for presentation validates the scientific rigor of our approach to treating type 2 diabetes and other metabolic disorders, which have reached global epidemic proportions,” said Mark Weinreb, CEO of BioRestorative Therapies. “BRT’s presentation aligns with the meeting’s emphasis on cutting-edge approaches and original data, focusing on science and technology that will expand our knowledge and future applications of adult adipose-derived stem cells around the world.”

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:

  • brtxDISC™ (Disc Implanted Stem Cells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient’s own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
  • ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
  • brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Source: BioRestorative Therapies, Inc.

Released November 20, 2013